Engineered Tissue Patch for Cardiac Cell Therapy

被引：18
作者：
Zhang J. [1 ,2 ]
机构：
[1] Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, 55455, MN
[2] Cardiology, University of MN Health Science Center, 420 Delaware Street SE,, Mayo Mail Code 508, Minneapolis, 55455, MN
来源：
Current Treatment Options in Cardiovascular Medicine | 2015年 / 17卷 / 8期
基金：
美国国家卫生研究院;
关键词：
Heart failure; Infarction; Myocardium; Scaffold; Stem cell; Tissue engineering;
D O I：
10.1007/s11936-015-0399-5
中图分类号：
学科分类号：
摘要：
Cell therapy can be administered via injections delivered directly into the myocardium or as engineered cardiac tissue patches, which are the subject of this review. Engineered cardiac patches can be created from sheets of interconnected cells or by suspending the cells in a scaffold of material that is designed to mimic the native extracellular matrix. The sheet-based approach produces patches with well-aligned and electronically coupled cardiomyocytes, but cell-containing scaffolds are more readily vascularized by the host’s circulatory system and, consequently, are currently more suitable for applications that require a thicker patch. Cell patches can also be modified for the co-delivery of peptides that may promote cell survival and activate endogenous repair mechanisms; nevertheless, techniques for controlling inflammation, limiting apoptosis, and improving vascular growth need continue to be developed to make it a therapeutic modality for patients with myocardial infarction. © 2015, Springer Science+Business Media New York.
引用
收藏
页数：10
相关论文
共 67 条
  • [1] Weir R.A., McMurray J.J., Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction, Curr Heart Failure Rep, 3, pp. 175-180, (2006)
  • [2] Lund L.H., Edwards L.B., Kucheryavaya A.Y., Dipchand A.I., Benden C., Christie J.D., Et al., The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report—2013
  • [3] focus theme: age, J Heart Lung Transplant, 32, (2013)
  • [4] Langer R., Vacanti J.P., Tissue engineering, Science, 260, pp. 920-926, (1993)
  • [5] Shimizu T., Yamato M., Isoi Y., Akutsu T., Setomaru T., Abe K., Et al., Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces, Circ Res, 90, (2002)
  • [6] Zimmermann W.H., Didie M., Wasmeier G.H., Nixdorff U., Hess A., Melnychenko I., Et al., Cardiac grafting of engineered heart tissue in syngenic rats, Circulation, 106, pp. 151-157, (2002)
  • [7] Li R.K., Jia Z.Q., Weisel R.D., Mickle D.A., Choi A., Yau T.M., Survival and function of bioengineered cardiac grafts, Circulation, 100, pp. 63-69, (1999)
  • [8] Leor J., Aboulafia-Etzion S., Dar A., Shapiro L., Barbash I.M., Battler A., Et al., Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium?, Circulation, 102, pp. 56-61, (2000)
  • [9] Zimmermann W.H., Melnychenko I., Wasmeier G., Didie M., Naito H., Nixdorff U., Et al., Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts, Nat Med, 12, pp. 452-458, (2006)
  • [10] Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., Et al., Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction, Nat Med, 12, pp. 459-465, (2006)
1234567